Definitive Healthcare Corp earnings date
Want to see DH full AI Analyst Report?
Definitive Healthcare Corp (DH) Q2 2026 Earnings Report
DH Q2 2026 EPS Results
- Actual EPS
- $0.05
- Consensus EPS
- $0.04
- Beat/Miss
- Beat by +$0.01
- One Year Ago EPS
- $0.07
DH Q2 2026 Revenue Results
- Actual Revenue
- $55.20M
- Expected Revenue
- $55.47M
- Beat/Miss
- Missed by -$279.00K
- YoY Revenue Growth
- -9.14%
Earnings Announcement Details
- Quarter
- Q2 2026
- Date
- 08/10/2026
- Time
- After Close
- Conference Call
- Monday, August 10, 2026
Definitive Healthcare Corp's next earnings date is estimated for March 4, 2027, based on past reporting schedules.
Q2 2026 Earnings Call Audio
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
The call conveyed a balanced message: clear near‑term top‑line pressures (Q2 revenue down 9% YoY, RPO and deferred revenue down double digits, professional services softness, and continued life sciences drag) alongside strong profitability, disciplined cost management, robust free cash flow (~$50M TTM), operational progress (integrations, win‑backs, digital activation growth), and product/AI momentum (Turbo pilot and AI embedding). Management tightened full‑year revenue guidance while raising profit/margin guidance and emphasized that improvements in net dollar retention and customer win‑backs underpin confidence in a return to growth over time.
Definitive Healthcare said Q2 results informed a tightened outlook: Q2 revenue was $55.2M (‑9% YoY) with adjusted EBITDA $14.6M (26% margin), adjusted net income $7.5M ($0.05 non‑GAAP EPS), adjusted gross profit $44.2M (80% margin, down 12% YoY but +100bps ex‑one‑time credit), unlevered free cash flow $11.6M in Q2 and $50M TTM, deferred revenue $89M (‑12% YoY), total RPO down 18% YoY and current RPO $150M (‑12% YoY), and a TTM adjusted EBITDA→unlevered FCF conversion of 75% (down ~5pts). For Q3 they guide revenue $54–55M (‑8% to ‑10% YoY) with subscription revenue flat sequential, professional services expected to show double‑digit growth but below prior expectations, adjusted operating income $10.5–11.5M, adjusted EBITDA $13.5–14.5M (25–27% margin), adjusted net income $5.5–6.5M and EPS ~$0.04–0.05 on ~145M shares. Full‑year 2026 guidance is revenue $220–222M (‑8% to ‑9% YoY), adjusted operating income $45.5–47.5M, adjusted EBITDA $57–59M (26–27% margin), adjusted net income $27–29M and EPS $0.18–0.20 on ~145M shares; management tightened top‑line visibility, lowered professional services expectations, but raised the EBITDA midpoint by $1M and expanded margin guidance ~100bps.
- Profitability Above GuidanceAdjusted EBITDA of $14.6M in Q2 with a 26% margin, modestly above the high end of guidance; full-year adjusted EBITDA guidance raised to $57M–$59M (26%–27% margin) and midpoint increased by $1M.
- Strong Free Cash Flow GenerationGenerated approximately $50M of unlevered free cash flow on a trailing 12‑month basis; Q2 unlevered free cash flow of $11.6M and operating cash flow over $41M TTM; EBITDA-to-free-cash conversion ~75% (down ~5 pts YoY due to unique prior-year items).
- Revenue and Subscription TransparencyQ2 total revenue of $55.2M and subscription revenue of $52.8M, both within guidance ranges, with disclosure of trends and drivers to align investor expectations.
- Improving Net Dollar RetentionNet dollar retention improved year-over-year on a trailing 12‑month basis for the second consecutive quarter, cited as an important proof point for future growth and retention improvements.
- Product & AI Innovation (Turbo) and Pilot ProgressLaunched Turbo pilot (AI-powered healthcare intelligence platform) with strategic customers; GA targeted before year-end 2026. Management does not expect material 2026 revenue from Turbo but sees retention and 2027 upside potential; AI embedded across data collection and products.
- Integration and Time-to-Value ImprovementsCompleted over 50% more integrations YoY while reducing time-to-integrate by more than 50%, enabling faster customer adoption and at least one example of an early renewal and expansion via Salesforce-embedded connector.
- Customer Wins, Win-Backs and Activation MomentumBiopharma had its strongest new-business quarter in 3 years (outside Q4) and the company secured 4 important win‑back customers; added a 6‑figure 3‑year win‑back in diversified. Digital activation: 10 new agency partners (active in 2026), 7 new direct activation customers YTD, and at least one activation customer expanded to >$300K.
- Gross Margin Context and ImprovementAdjusted gross profit of $44.2M (80% margin) down 12% YoY as reported; after adjusting for a one-time Q2 2025 data-contract credit, adjusted gross margin expanded ~100 basis points YoY.
- Targeted Investment DisciplineContinued disciplined expense management while increasing capitalized software development to >$2M in Q2 (up ~$700K YoY) to support AI/product investments without sacrificing margins.
DH Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 04, 2027 | 2026 (Q4) | 0.04- | 0.06 | ― | ― |
| Nov 05, 2026 | 2026 (Q3) | 0.040.06 | 0.07 | -14.29% (-0.01) | |
| Aug 10, 2026 | 2026 (Q2) | 0.040.05 | 0.07 | -28.57% (-0.02) | |
| May 07, 2026 | 2026 (Q1) | 0.030.06 | 0.05 | 20.00% (+0.01) | |
| Feb 26, 2026 | 2025 (Q4) | 0.060.06 | 0.08 | -25.00% (-0.02) | |
| Nov 06, 2025 | 2025 (Q3) | 0.060.07 | 0.1 | -30.00% (-0.03) | |
| Aug 07, 2025 | 2025 (Q2) | 0.050.07 | 0.09 | -22.22% (-0.02) | |
| May 08, 2025 | 2025 (Q1) | 0.020.05 | 0.08 | -37.50% (-0.03) | |
| Feb 27, 2025 | 2024 (Q4) | 0.070.08 | 0.07 | 14.29% (+0.01) | |
| Nov 07, 2024 | 2024 (Q3) | 0.080.10 | 0.09 | 11.11% (+0.01) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


